Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Miscellaneous Drugs

Last Updated: December 1, 2022

Summary Recommendations
Summary Recommendations

Colchicine

  • The COVID-19 Treatment Guidelines Panel (the Panel) recommends against the use of colchicine for the treatment of nonhospitalized patients with COVID-19, except in a clinical trial (BIIa).
  • The Panel recommends against the use of colchicine for the treatment of hospitalized patients with COVID-19 (AI).

Fluvoxamine

  • There is insufficient evidence for the Panel to recommend either for or against the use of fluvoxamine for the treatment of COVID-19.

Ivermectin

  • The Panel recommends against the use of ivermectin for the treatment of COVID-19, except in clinical trials (AIIa).

Intravenous Immunoglobulin

  • The Panel recommends against the use of intravenous immunoglobulin (IVIG) for the treatment of acute COVID-19 in adults and children, except in a clinical trial (AIII). This recommendation should not preclude the use of IVIG when otherwise indicated for the treatment of complications that arise during the course of COVID-19.
  • The Panel recommends using IVIG in combination with low to moderate dose glucocorticoids in hospitalized patients for the treatment of multisystem inflammatory syndrome in children (MIS-C) (AIIb).
  • The Panel recommends against the routine use of IVIG monotherapy for the treatment of MIS-C unless glucocorticoid use is contraindicated (AIIb).

Metformin

  • The Panel recommends against the use of metformin for the treatment of COVID-19 in nonhospitalized patients (BIIa) and hospitalized patients (BIII), except in a clinical trial.
  • Patients with COVID-19 who are receiving metformin for an underlying condition should continue this therapy as directed by their health care provider (AIII).
Each recommendation in the Guidelines receives 2 ratings that reflect the strength of the recommendation and the quality of the evidence that supports it. See Guidelines Development for more information.